ProSci

Human TNFSF13B/BAFF/CD257 Recombinant Protein (85-742)

Product Code:
PSI-85-742
Product Group:
Recombinant Proteins
Supplier:
ProSci
Regulatory Status:
RUO
Target Species:
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunogen
  • SDS-PAGE
  • Western Blot (WB)
Product Types:
  • CD Proteins
  • Cytokines and Other Signalling
  • Growth Factors
  • TNFs
Shipping:
RT
Storage:
Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.
 

No additional charges, what you see is what you pay! *

Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Application Note:
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity Test
Background:
B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.
Buffer:
Lyophilized from a 0.22 um filtered solution of PBS, pH 7.4.
NCBI Gene ID:
10673
Physical State:
Lyophilized
Predicted MW:
17.88 kDa
Protein Accession:
NP_006564.1
Source Species:
HEK293 cells
SwissProt:
Q9Y275

Documents